Mallinckrodt buying Cadence Pharma for $1.21B

Health care products company Mallinckrodt is buying Cadence Pharmaceuticals Inc. for about $1.21 billion to help enhance its specialty pharmaceuticals segment.

San Diego-based Cadence is a that concentrates on commercializing products most for use at hospitals.

Ireland's Mallinckrodt PLC will pay $14 per , a 27 percent premium to Cadence's Monday closing price of $1107. The companies put the 's value at about $1.3 billion.

Cadence has approximately 86.1 million outstanding shares, according to FactSet.

Both companies' boards unanimously approved the transaction.

Cadence will become a Mallinckrodt subsidiary.

Mallinckrodt said Tuesday that it expects the acquisition to immediately add to its fiscal 2014 adjusted earnings per share and significantly add to its fiscal 2015 adjusted earnings per share.

The deal is targeted to close in mid- to late-March.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

IBM posts higher 4Q net income (Update)

Jan 21, 2014

IBM's fourth-quarter net income grew 6 percent, surpassing Wall Street's expectations even though revenue fell. Its shares fell in extended trading after the results came out—and CEO Ginni Rometty said she's recommending ...

News Corp fiscal 2Q earns top expectations

Feb 06, 2014

News Corp., the publishing company controlled by Rupert Murdoch, reported second-quarter earnings that exceeded Wall Street forecasts while revenue declined as expected, reflecting slower advertising sales.

Recommended for you

Errata frequently seen in medical literature

17 hours ago

(HealthDay)—Errata, including those that may materially change the interpretation of data, are frequent in medical publications, according to a study published in the August issue of The American Journal of ...

Seven US-based researchers share $1.3M eyesight prize

Sep 10, 2014

Seven U.S.-based researchers are sharing a €1 million ($1.3 million) prize from a Portuguese foundation for their work developing treatment for angiogenic diseases of the retina, the leading cause of blindness in the developed ...

User comments